Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis

The programmed cell death 4 gene (PDCD4), a newly identified transformation suppressor, was analysed in lung tumour cell lines and primary lung carcinomas. Reduced PDCD4 mRNA expression was observed in two immortalized lung cell lines and 18 cancer cell lines by northern blot analysis. In the survey of primary lung tumours, PDCD4 cDNA was poorly represented in 47 lung tumours compared with normal lung tissue by cDNA microarray analysis and this poor representation was significantly associated with high‐grade (G3) adenocarcinomas (p = 0.012). Immunohistochemical analysis of 124 primary carcinomas comprising all subtypes demonstrated that PDCD4 protein expression was widely lost in tumour samples (83%) and was negatively related to poor prognosis (p = 0.013). The loss of PDCD4 expression correlated with higher grade and disease stage (p = 0.045 and 0.034, respectively), but not tumour size and nodal status. Similarly to the cDNA data, lack of PDCD4 expression was significantly linked to tumour grade in adenocarcinoma (n = 59, p = 0.048), while in squamous cell carcinoma (n = 58), no relationship between PDCD4 expression and clinicopathological parameters was established. These data suggest that the loss of PDCD4 expression is a prognostic factor in lung cancer and may correlate with tumour progression. Copyright © 2003 John Wiley & Sons, Ltd.

[1]  M. Pacyna‐Gengelbach,et al.  Gene expression profiles in human non-small and small-cell lung cancers. , 2003, European journal of cancer.

[2]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[3]  H. Kizaki,et al.  Cloning of the TIS gene suppressed by topoisomerase inhibitors. , 1998, Gene.

[4]  K. Klempnauer,et al.  The chicken Pdcd4 gene is regulated by v-Myb , 2001, Oncogene.

[5]  G. Strauss The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Honjo,et al.  Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. , 1995, Gene.

[7]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[8]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[9]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[10]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Petersen,et al.  Gene expression profiling of advanced lung cancer , 2000, International journal of cancer.

[12]  M. D. David S. Schrump,et al.  Targets for Molecular Intervention in Multistep Pulmonary Carcinogenesis , 2001, World Journal of Surgery.

[13]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[14]  M. Volm,et al.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.

[15]  Spyro Mousses,et al.  Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. , 2002, Cancer research.

[16]  N. Colburn,et al.  Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Sasaki,et al.  Expression of the sensitive to apoptosis gene, SAG, as a prognostic marker in nonsmall cell lung cancer , 2001, International journal of cancer.

[18]  O. Kallioniemi,et al.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.

[19]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[20]  C. Fujiyama,et al.  Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti‐H731 antibody , 1999, Pathology international.

[21]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[22]  N. Colburn,et al.  A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation , 2001, Oncogene.

[23]  H. Moch,et al.  Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.

[24]  Aaron P. Campbell,et al.  Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.